Oral-Turinabol
Stan · Oral turinabol · Oral turinabo · turinabol-oral · Turinabol 25mg · 4-Chlorodianabol · 4-Chlordehydromethyl · turinabol-oral Tbol
Identifiers & Physical Properties
| CAS No. | 2446-23-3 |
|---|---|
| Molecular formula | C20H27ClO2 |
| Average molar mass | 334.9 g/mol |
| Monoisotopic mass | 334.1699578 g/mol |
| SMILES | C[C@]12C=CC(=O)C(Cl)=C1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O |
| InChIKey | AGUNEISBPXQOPA-XMUHMHRVSA-N |
| PubChem CID | 98521 |
| ChEBI | CHEBI:166768 |
| EC No. | 962-211-2 |
| DTXSID | DTXSID10179216 |
Chemical & Physical Properties
| XLogP | 4.4 |
|---|---|
| Topological polar surface area | 37.3 |
| Hydrogen bond donors | 1 |
| Hydrogen bond acceptors | 2 |
| Rotatable bonds | 0 |
| Heavy atoms | 23 |
| Formal charge | 0 |
| Complexity | 636 |
| Drugs | DEA NFLIS-Drug Category -> SteroidsDEA Schedule III Controlled Substance -> Anabolic steroids |
| Endocrine Disruptors | Potential endocrine disrupting compound |
| Melting point | 125 - 127 °C149-151 °C(Solv: acetone (67-64-1)hexane (110-54-3)) |
| Physical Description | Solid |
| Boiling point | 464.4±45.0 °C(Predicted) |
| Density | 1.20±0.1 g/cm3(Predicted) |
| Solubility | Acetonitrile: 1 mg/mlEthanol: 1 mg/mlMethanol: 1 mg/ml |
| Physical state | A crystalline solid |
| pKa (acidity coefficient) | 15.05±0.70(Predicted) |
| InChI | InChI=1/C20H27ClO2/c1-18-9-8-16(22)17(21)15(18)5-4-12-13(18)6-10-19(2)14(12)7-11-20(19,3)23/h8-9,12-14,23H,4-7,10-11H2,1-3H3/t12-,13+,14+,18-,19+,20+/s3 |
| InChIKey | AGUNEISBPXQOPA-RFNNMYDSNA-N |
| SMILES | C[C@]12C=CC(=O)C(Cl)=C1CC[C@@]1([H])[C@]3([H])CC[C@@](O)(C)[C@@]3(C)CC[C@]21[H] |&1:1,11,13,17,20,24,r| |
| FDA UNII | ZPZ473F40K |
| DEA Controlled Substances | CSCN: 4000CSA SCH: Schedule IIINARC: No |
Safety & Regulations
| GHS classification | DangerH350 (50%): May cause cancer [Danger Carcinogenicity]P203, P260, P263, P264, P270, P273, P280, P318, P319, P391, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 2 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| Regulatory information | DEA schedule III controlled substance |
| Hazard Classes and Categories | Carc. 1B (50%) |
| DEA Controlled Substances | CSCN: 4000CSA SCH: Schedule IIINARC: No |
Applications & Uses
Description
4-Chlorodehydromethyltestosterone (CDMT; brand name Oral Turinabol), also known as Chlorodehydromethyltestosterone, is an anabolic–androgenic steroid (AAS). It is the 4-chloro-substituted derivative of metandienone (dehydromethyltestosterone). Turinabol is indicated for hormone replacement therapy in men suffering from androgen deficiency or in severe cases of catabolism.
History
4-Chlorodehydromethyltestosterone is an anabolic steroid developed in the 1960s, a highly competitive time for the Olympics and national level sports, the East German experts were looking for effective steroids that would circumvent these sports'drug testing policies. The product was introduced for clinical use in 1965 and remained in use until 1994, when production was discontinued.
Uses
4-Chlorodehydromethyltestosterone is a derivative of dehydrochloromethyltestosterone. Metabolite of anabolic steroids. it can produce quality gains in muscle mass as well as strength, even if these gains are not as dramatic or quick as you might get from an aromatizable, or more androgenic oral steroid.
General Description
Dehydrochloromethyl Testosterone is an analytical reference standard that is categorized as an androgenic anabolic steroid. Anabolic steroids, including dehydrochloromethyl testosterone, have been used to enhance physical performance in athletes. Dehydrochloromethyl testosterone is regulated as a Schedule III compound in the United States. This product is intended for research and forensic applications.